Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures
- 7 September 2001
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 7 (5), 517-522
- https://doi.org/10.1046/j.1365-2516.2001.00553.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIaBlood, 2000
- Clinical Use of Recombinant FVIIa (rFVIIa)Transfusion Science, 1998
- Clinical experience with recombinant factor VIIaBlood Coagulation & Fibrinolysis, 1998
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997
- Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activationThrombosis Research, 1994
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaCancer Cell, 1994
- Pharmacokinetic dosing in prophylactic treatment of hemophilia AEuropean Journal of Haematology, 1993
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988
- Haemophilia in Sweden VII. Incidence, Treatment and Prophylaxis of Arthropathy and other Musculo-Skeletal Manifestations of Haemophilia A and BActa Orthopaedica, 1965